| Followers | 21 |
| Posts | 946 |
| Boards Moderated | 0 |
| Alias Born | 07/20/2020 |
Saturday, May 29, 2021 5:58:07 PM
I see that they got approval after 583 patients and state that " There are no adequate, approved and available alternative treatments to sotrovimab." However, Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research states “It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of COVID-19 in the United States.”
Maybe they will throw us a bone to give doctors options. It's third down and 17. Should we hold the hail mary pass or wait until 4th down?
ps. Reluctantly, and slightly annoyed, we wait.
Maybe they will throw us a bone to give doctors options. It's third down and 17. Should we hold the hail mary pass or wait until 4th down?
ps. Reluctantly, and slightly annoyed, we wait.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
